Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central Italy-Reference-Cited by-同舟云学术

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central Italy

Published:2022-10-31 Issue:6 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Ripabelli Giancarlo¹²^ORCID,Sammarco Michela Lucia¹,D’Amico Antonio²,De Dona Roberta²,Iafigliola Mariagrazia²,Parente Albino²,Samprati Nicandro²,Santagata Arturo²,Adesso Carmen²,Natale Anna²,Di Palma Michela Anna²,Cannizzaro Fabio²,Romano Roberto³,Licianci Antonietta³,Tamburro Manuela¹

Affiliation:

1. Department of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, Campobasso, Italy

2. School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy

3. Antonio Cardarelli Hospital, Azienda Sanitaria Regionale del Molise, Campobasso, Italy

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2126668

Reference33 articles.

1. Addressing Parental Vaccine Hesitancy and Other Barriers to Childhood/Adolescent Vaccination Uptake During the Coronavirus (COVID-19) Pandemic

2. Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?

3. Vaccinating Children against Covid-19 — The Lessons of Measles

4. Food and Drug Administration. FDA authorizes Pfizer-BioNtech COVID-19 vaccine for emergency use in children 5 through 11 years of age; 2021 Oct 29 [accessed 2022 Mar 16]. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.

5. European Medicines Agency. Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11; 2021 Nov 25 [accessed 2022 Apr 11]. https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaçao, the Caribbean;Infectious Diseases;2024-09-03

2. Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5–11 years with underlying diseases: A prospective observational study;Journal of Infection and Chemotherapy;2024-08

3. Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China;Diagnostic Microbiology and Infectious Disease;2024-06

4. Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis;Informatics in Medicine Unlocked;2024

5. Effectiveness of the BNT162b2 vaccine in preventing morbidity and mortality associated with COVID-19 in children aged 5 to 11 years: A systematic review and meta-analysis;PLOS Global Public Health;2023-12-04